{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:13:54Z","timestamp":1780449234962,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Duchenne muscular dystrophy (DMD) is a rare, severe, fatal neuromuscular disease characterized by progressive atrophy and muscle weakness, resulting in loss of ambulation, decreased upper body function, and impaired cardiorespiratory function. This study aimed to generate qualitative evidence to describe the primary symptoms and impacts of DMD in ambulatory and non-ambulatory patients as reported by patient\/caregiver dyads. Information was also gathered on expectations for future DMD treatments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Forty-six dyads (caregiver and patients with DMD aged 4 to 22\u00a0years) participated in 60-min semi-structured video interviews. Interview transcripts were analyzed using thematic analysis. Differences in experiences with DMD by ambulation status were examined.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean ages of ambulatory (n\u2009=\u200928) and non-ambulatory participants (n\u2009=\u200918) were 8.7 and 11.3\u00a0years, respectively, with an average age of diagnosis of 3.7\u00a0years (SD\u2009=\u20092.3). The primary symptoms reported by both groups were lack of strength (ambulatory: n\u2009=\u200928, 100.0%; non-ambulatory: n\u2009=\u200917, 94.4%) and fatigue (ambulatory: n\u2009=\u200924, 85.7%; non-ambulatory: n\u2009=\u200914, 77.8%). Physical function was the domain that was most impacted by DMD, with participants describing progressive decline of physical function due to loss of physical strength as the primary defining feature of the disease across all stages of ambulatory ability. For those who maintained ambulatory ability at the time of the interview, physical function impacts described impaired mobility (e.g., climbing stairs: n\u2009=\u200916, 57.1%; running: n\u2009=\u200913, 46.4%), impaired upper body function, in particular fine motor skills like holding a pen\/pencil or buttoning clothes (n\u2009=\u200917, 60.7%), problem with transfers (e.g., getting off the floor: n\u2009=\u200910, 35.7%), and activities of daily living (ADLs; n = 15, 53.6%). For non-ambulatory participants, the functional impacts most frequently described were problems with transfers (e.g., getting in\/out of bed: n\u2009=\u200913, 72.2%; getting in\/out of chair or position in bed: both n\u2009=\u200910, 55.6%), impaired upper body function (reaching: n\u2009=\u200914, 77.8%), and ADLs (n\u2009=\u200915, 83.3%). Meaningful treatment goals differed by ambulatory status; for ambulatory participants, goals included maintaining current functioning (n\u2009=\u200920, 71.4%), improving muscle strength (n\u2009=\u20097, 25.9%), and reducing fatigue (n\u2009=\u20096, 22.2%). For non-ambulatory participants, these included increased upper body strength (n\u2009=\u20098, 42.1%) and greater independence in ADLs (n\u2009=\u20096, 31.6%). A preliminary conceptual model was developed to illustrate the primary symptoms and physical function impacts of DMD and capture their relationship to disease progression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study contributes to the limited qualitative literature by characterizing impacts of physical limitations and symptoms of DMD on disease progression and thus providing insights into the lived experience with DMD. Differences in treatment goals were also identified based on ambulatory status. Taken together, these findings can help inform patient-centered measurement strategies for evaluating outcomes in DMD clinical research.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-023-00669-6","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T09:22:12Z","timestamp":1702372932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A qualitative study to understand the Duchenne muscular dystrophy experience from the parent\/patient perspective"],"prefix":"10.1186","volume":"7","author":[{"given":"Victoria","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Merikle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Gooch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Audhya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Lowes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"669_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-u","volume":"1","author":"AE Emery","year":"1991","unstructured":"Emery AE (1991) Population frequencies of inherited neuromuscular diseases\u2014a world survey. Neuromuscul Disord 1:19\u201329. https:\/\/doi.org\/10.1016\/0960-8966(91)90039-u","journal-title":"Neuromuscul Disord"},{"key":"669_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z et al (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74:637\u2013647. https:\/\/doi.org\/10.1002\/ana.23982","journal-title":"Ann Neurol"},{"key":"669_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3390\/genes11080837","volume":"11","author":"C Sun","year":"2020","unstructured":"Sun C, Shen L, Zhang Z, Xie X (2020) Therapeutic strategies for Duchenne muscular dystrophy: an update. Genes (Basel) 11:837. https:\/\/doi.org\/10.3390\/genes11080837","journal-title":"Genes (Basel)"},{"key":"669_CR4","doi-asserted-by":"publisher","first-page":"18168","DOI":"10.3390\/molecules201018168","volume":"20","author":"MS Falzarano","year":"2015","unstructured":"Falzarano MS, Scotton C, Passarelli C, Ferlini A (2015) Duchenne muscular dystrophy: from diagnosis to therapy. Molecules 20:18168\u201318184. https:\/\/doi.org\/10.3390\/molecules201018168","journal-title":"Molecules"},{"key":"669_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A (2021) Duchenne muscular dystrophy. Nat Rev Dis Primers 7:13. https:\/\/doi.org\/10.1038\/s41572-021-00248-3","journal-title":"Nat Rev Dis Primers"},{"key":"669_CR6","volume-title":"Neuromuscular disorders of infancy, childhood, and adolescence: a clinician's approach","author":"HR Jones","year":"2003","unstructured":"Jones HR, De Vivo DC, Darras BT (2003) Neuromuscular disorders of infancy, childhood, and adolescence: a clinician\u2019s approach. Butterworth-Heinemann, Philadelphia"},{"key":"669_CR7","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","volume":"394","author":"E Mercuri","year":"2019","unstructured":"Mercuri E, Bonnemann CG, Muntoni F (2019) Muscular dystrophies. Lancet 394:2025\u20132038. https:\/\/doi.org\/10.1016\/S0140-6736(19)32910-1","journal-title":"Lancet"},{"key":"669_CR8","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1212\/WNL.0000000000002147","volume":"85","author":"L Peverelli","year":"2015","unstructured":"Peverelli L, Testolin S, Villa L et al (2015) Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophy. Neurology 85:1886\u20131893. https:\/\/doi.org\/10.1212\/WNL.0000000000002147","journal-title":"Neurology"},{"key":"669_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/ijns5030027","volume":"5","author":"A Timonen","year":"2019","unstructured":"Timonen A, Lloyd-Puryear M, Hougaard DM et al (2019) Duchenne muscular dystrophy newborn screening: evaluation of a new GSP\u00ae neonatal creatine kinase-MM kit in a US and Danish population. Int J Neonatal Screen 5:27. https:\/\/doi.org\/10.3390\/ijns5030027","journal-title":"Int J Neonatal Screen"},{"key":"669_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 17:347\u2013361. https:\/\/doi.org\/10.1016\/S1474-4422(18)30025-5","journal-title":"Lancet Neurol"},{"key":"669_CR11","unstructured":"Munot P (2022) BMJ best practice: muscular dystrophies. https:\/\/bestpractice.bmj.com\/topics\/en-us\/969. Accessed 2 Jun 2023."},{"key":"669_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","volume":"12","author":"S Ryder","year":"2017","unstructured":"Ryder S, Leadley RM, Armstrong N et al (2017) The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis 12:79. https:\/\/doi.org\/10.1186\/s13023-017-0631-3","journal-title":"Orphanet J Rare Dis"},{"key":"669_CR13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol 17:445\u2013455. https:\/\/doi.org\/10.1016\/S1474-4422(18)30026-7","journal-title":"Lancet Neurol"},{"key":"669_CR14","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2106\/JBJS.L.01577","volume":"95","author":"DE Lebel","year":"2013","unstructured":"Lebel DE, Corston JA, McAdam LC, Biggar WD, Alman BA (2013) Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up. J Bone Joint Surg Am 95:1057\u20131061. https:\/\/doi.org\/10.2106\/JBJS.L.01577","journal-title":"J Bone Joint Surg Am"},{"key":"669_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3233\/JND-180351","volume":"6","author":"N Khan","year":"2019","unstructured":"Khan N, Eliopoulos H, Han L et al (2019) Eteplirsen treatment attenuates respiratory decline in ambulatory and non-ambulatory patients with Duchenne muscular dystrophy. J Neuromuscul Dis 6:213\u2013225. https:\/\/doi.org\/10.3233\/JND-180351","journal-title":"J Neuromuscul Dis"},{"key":"669_CR16","unstructured":"Iff J, Bungey G, Paine A, et al (2021) Delay of loss of ambulation with eteplirsen versus standard of care in Duchenne muscular dystrophy. In: Presented at the 2021 muscular dystrophy association virtual clinical and scientific conference, 15\u221218 Mar 2021"},{"key":"669_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/mus.27662","volume":"66","author":"J Iff","year":"2022","unstructured":"Iff J, Gerrits C, Zhong Y et al (2022) Delays in pulmonary decline in eteplirsen-treated patients with Duchenne muscular dystrophy. Muscle Nerve 66:262\u2013269. https:\/\/doi.org\/10.1002\/mus.27662","journal-title":"Muscle Nerve"},{"key":"669_CR18","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3233\/JND-210643","volume":"8","author":"CM McDonald","year":"2021","unstructured":"McDonald CM, Shieh PB, Abdel-Hamid HZ et al (2021) Open-label evaluation of eteplirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping: PROMOVI trial. J Neuromuscul Dis 8:989\u20131001. https:\/\/doi.org\/10.3233\/JND-210643","journal-title":"J Neuromuscul Dis"},{"key":"669_CR19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3233\/JND-200548","volume":"8","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Khan N, Sha N et al (2021) Comparison of long-term ambulatory function in patients with Duchenne muscular dystrophy treated with eteplirsen and matched natural history controls. J Neuromuscul Dis 8:469\u2013479. https:\/\/doi.org\/10.3233\/JND-200548","journal-title":"J Neuromuscul Dis"},{"key":"669_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3233\/JND-210665","volume":"9","author":"O Mitelman","year":"2022","unstructured":"Mitelman O, Abdel-Hamid HZ, Byrne BJ et al (2022) A combined prospective and retrospective comparison of long-term functional outcomes suggests delayed loss of ambulation and pulmonary decline with long-term eteplirsen treatment. J Neuromuscul Dis 9:39\u201352. https:\/\/doi.org\/10.3233\/JND-210665","journal-title":"J Neuromuscul Dis"},{"key":"669_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/nat.2021.0043","volume":"32","author":"L Servais","year":"2022","unstructured":"Servais L, Mercuri E, Straub V et al (2022) Long-term safety and efficacy data of golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1\/2 trial. Nucleic Acid Ther 32:29\u201339. https:\/\/doi.org\/10.1089\/nat.2021.0043","journal-title":"Nucleic Acid Ther"},{"key":"669_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12955-021-01813-w","volume":"19","author":"H Staunton","year":"2021","unstructured":"Staunton H, Trennery C, Arbuckle R et al (2021) Development of a clinical global impression of change (CGI-C) and a caregiver global impression of change (CaGI-C) measure for ambulant individuals with Duchenne muscular dystrophy. Health Qual Life Outcomes 19:184. https:\/\/doi.org\/10.1186\/s12955-021-01813-w","journal-title":"Health Qual Life Outcomes"},{"key":"669_CR23","unstructured":"ELEVIDYS (delandistrogene moxeparvovec-rokl) injection, for intravenous use [package insert]. Sarepta Therapeutics, Inc., Cambridge, MA (2023)"},{"issue":"1 suppl","key":"669_CR24","doi-asserted-by":"publisher","first-page":"S218","DOI":"10.1016\/j.jval.2021.11.1064","volume":"25","author":"J Iff","year":"2022","unstructured":"Iff J, McKee S, Johnson C et al (2022) Conceptual models of the patient experience of Duchenne muscular dystrophy constructed from a qualitative interview study with caregivers. Value Health 25(1 suppl):S218","journal-title":"Value Health"},{"key":"669_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11136-022-03240-w","volume":"32","author":"PA Powell","year":"2023","unstructured":"Powell PA, Carlton J (2023) A comprehensive qualitative framework for health-related quality of life in Duchenne muscular dystrophy. Qual Life Res 32:225\u2013236. https:\/\/doi.org\/10.1007\/s11136-022-03240-w","journal-title":"Qual Life Res"},{"key":"669_CR26","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1111\/hsc.13567","volume":"30","author":"VN Williams","year":"2022","unstructured":"Williams VN, McManus BM, Brooks-Russell A et al (2022) A qualitative study of effective collaboration among nurse home visitors, healthcare providers and community support services in the United States. Health Soc Care Community 30:1881\u20131893. https:\/\/doi.org\/10.1111\/hsc.13567","journal-title":"Health Soc Care Community"},{"key":"669_CR27","unstructured":"Brown V, Merikle E, Johnston K, Audhya I, Gooch K, Lowes L (2022) A qualitative study to understand the Duchenne muscular dystrophy experience from the caregiver\/patient perspective. In: Poster presentation at the Muscular Dystrophy Association (MDA) conference, Nashville, 13\u201316 Mar 2022"},{"key":"669_CR28","volume-title":"Handbook of research methods in psychology","author":"A Bryant","year":"2012","unstructured":"Bryant A, Charmaz K (2012) Grounded theory and psychological research. In: Cooper H (ed) Handbook of research methods in psychology, vol 2, Research Designs. American Psychological Association, Washington, DC"},{"key":"669_CR29","volume-title":"Basics of qualitative research: techniques and procedures for developing grounded theory","author":"ACJ Strauss","year":"1998","unstructured":"Strauss ACJ (1998) Basics of qualitative research: techniques and procedures for developing grounded theory, 2nd edn. Sage, Thousand Oaks CA","edition":"2"},{"issue":"1","key":"669_CR30","doi-asserted-by":"publisher","first-page":"160940691770298","DOI":"10.1177\/1609406917702983","volume":"16","author":"KKF Cheng","year":"2017","unstructured":"Cheng KKF, Clark AM (2017) Qualitative methods and patient-reported outcomes: measures development and adaptation. Int J Qual Methods 16(1):1609406917702983. https:\/\/doi.org\/10.1177\/1609406917702983","journal-title":"Int J Qual Methods"},{"key":"669_CR31","doi-asserted-by":"publisher","first-page":"e0213649","DOI":"10.1371\/journal.pone.0213649","volume":"14","author":"H Landrum Peay","year":"2019","unstructured":"Landrum Peay H, Fischer R, Tzeng JP et al (2019) Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: a qualitative preference study of patients and parents. PLoS ONE 14:e0213649. https:\/\/doi.org\/10.1371\/journal.pone.0213649","journal-title":"PLoS ONE"},{"key":"669_CR32","unstructured":"United States Food and Drug Administration (2022) Patient-focused drug development: methods to identify what is important to patients: guidance for industry, food and drug administration staff, and other stakeholders. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients. Accessed 15 Sept 2023"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00669-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-023-00669-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00669-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T09:26:13Z","timestamp":1702373173000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-023-00669-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["669"],"URL":"https:\/\/doi.org\/10.1186\/s41687-023-00669-6","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]},"assertion":[{"value":"28 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the NCH Hospital Internal Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"VB, EM, and KJ are employees of Fortrea Inc. (formerly Labcorp Drug Development Inc.), which was funded by Sarepta Therapeutics, Inc., to conduct the interviews. KG and IA are employees of Sarepta Therapeutics, Inc., and may own stock\/options. LL recruited and screened patients for this study; she is an employee of NCH, which receives grant funding for other research initiatives from Sarepta Therapeutics, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}